BLUE bluebird bio Inc

Price (delayed)

$4.4

Market cap

$314.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.48

Enterprise value

$318.47M

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights
The revenue has surged by 66% year-on-year
bluebird bio's debt has decreased by 46% YoY but it has increased by 23% from the previous quarter
The company's net income fell by 18% YoY but it rose by 10% QoQ
The gross profit has plunged by 154% YoY and by 48% from the previous quarter
bluebird bio's equity has plunged by 78% YoY and by 30% from the previous quarter

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
71.45M
Market cap
$314.4M
Enterprise value
$318.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
-$7.19M
EBIT
-$735.81M
EBITDA
-$720.5M
Free cash flow
-$565.34M
Per share
EPS
-$10.48
Free cash flow per share
-$7.67
Book value per share
$3.69
Revenue per share
-$0.1
TBVPS
$6.59
Balance sheet
Total assets
$491.07M
Total liabilities
$227.81M
Debt
$110.34M
Equity
$263.26M
Working capital
$112.03M
Liquidity
Debt to equity
0.42
Current ratio
1.78
Quick ratio
1.56
Net debt/EBITDA
-0.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-75.9%
Return on equity
-118.1%
Return on invested capital
-114.9%
Return on capital employed
-211.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
2.8%
1 week
23.6%
1 month
49.66%
1 year
-86.39%
YTD
-55.96%
QTD
-9.28%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
-$7.19M
Gross profit
-$52.07M
Operating income
-$480.42M
Net income
-$735.72M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 154% YoY and by 48% from the previous quarter
The revenue has surged by 66% year-on-year
bluebird bio's operating income has increased by 19% from the previous quarter and by 3.7% YoY
The company's net income fell by 18% YoY but it rose by 10% QoQ

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
1.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 12% since the previous quarter but it has declined by 11% year-on-year
bluebird bio's equity has plunged by 78% YoY and by 30% from the previous quarter
BLUE's P/B is 64% below its 5-year quarterly average of 3.3 and 30% below its last 4 quarters average of 1.7
The revenue has surged by 66% year-on-year

Efficiency

How efficient is bluebird bio business performance
bluebird bio's ROE has plunged by 173% YoY and by 24% from the previous quarter
bluebird bio's return on invested capital has shrunk by 132% YoY and by 19% QoQ
bluebird bio's ROA has plunged by 128% YoY and by 16% from the previous quarter

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The total assets is 116% greater than the total liabilities
The total assets has dropped by 70% year-on-year and by 17% since the previous quarter
The quick ratio has plunged by 69% YoY and by 23% from the previous quarter
bluebird bio's debt is 58% less than its equity
BLUE's debt to equity has surged by 147% year-on-year and by 75% since the previous quarter
bluebird bio's equity has plunged by 78% YoY and by 30% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.